Atlas Trials

Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis

Clinical trial NCT03816891 · COMPLETED

Trial details

NCT number
NCT03816891
Sponsor
Genentech, Inc.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Prurigo NodularisPruritis
Start date
2019-03-11
Primary completion
2022-12-28
Enrollment
240

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.